Labetuzumab govitecan (IMMU-130) is an experimental antibody-drug conjugate (ADC) that targets cancers overexpressing CEACAM5, a protein found in many solid tumors, including colorectal cancer. It combines labetuzumab, a monoclonal antibody that binds to CEACAM5, with SN-38, the active form of irinotecan. A pH-sensitive linker directs SN-38 to cancer cells, boosting effectiveness and reducing side effects.
Key Features
- Targeted Therapy: Specifically binds to CEACAM5, delivering SN-38 directly to cancer cells.
- Mechanism of Action: Once attached to CEACAM5, the ADC enters the cancer cell and releases SN-38, which disrupts DNA replication, causing cell death.
- Precision Treatment: Focuses on CEACAM5-expressing cancer cells, reducing harm to healthy tissues.
Clinical Development
Labetuzumab govitecan has been tested in clinical trials for metastatic colorectal cancer (mCRC). In studies, it showed a disease control rate of 38% and improved progression-free survival in patients who no longer responded to irinotecan. Side effects like neutropenia and diarrhea were manageable.
Applications
- Colorectal Cancer: Treats metastatic colorectal cancer that overexpresses CEACAM5, especially in patients resistant to standard therapies.
- Other Solid Tumors: Explored for use in other CEACAM5-positive tumors, such as gastric and pancreatic cancers.
Labetuzumab govitecan offers a targeted approach to treating CEACAM5-positive cancers, aiming to enhance effectiveness and reduce toxicity.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
